MAPT and Alzheimer disease: Tau-targeted drugs may be a promising disease-modifying therapy because previous studies focusing on the correlation of AD neuropathological changes (Aβ plaques and NFT) with cognitive impairment have shown that the severity of cognitive impairment correlated best with the burden of abnormal tau (Nelson et al., 2012).